N4 Pharma (GB:N4P) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
N4 Pharma has granted 15 million options over ordinary shares to key directors, including CEO Nigel Theobold and Executive Director Luke Cairns, at an exercise price of 0.75p. These options, part of the company’s strategy to align leadership incentives with long-term growth, will vest in equal tranches over three years. This move underscores N4 Pharma’s commitment to advancing its innovative delivery systems for cancer treatments and vaccines.
For further insights into GB:N4P stock, check out TipRanks’ Stock Analysis page.